ithium trial bij ALS
- Conditions
- ALSamyotrophic lateral sclerosisamyotrofische laterale sclerose
- Registration Number
- NL-OMON20046
- Lead Sponsor
- Prof. dr. L.H. van den Berg, neurologist Dep. neurology, UMC-UtrechtHeidelberglaan 100/HP G03.2283584CX UtrechtTel: +31-88-7557939Fax: +31-30-2542100Email: L.H.vandenBerg@umcutrecht.nl
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 191
Inclusion Criteria
1. Definite, probable, or probable-laboratory supported ALS according to the revised El Escorial World Federation of Neurology criteria.
2. Intake of riluzole 2dd 50 mg
Exclusion Criteria
1. Tracheostomy, tracheostomal ventilation of any type, non-invasive ventilation more than 16 hours/ day, or supplemental oxygen during the last three months prior to inclusion.
2. Any medical condition or intoxication known to have an association with motor neuron dysfunction, which might confound or obscure the diagnosis of ALS.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Survival
- Secondary Outcome Measures
Name Time Method - The rate of decline in daily functioning